EnteroMedics (NASDAQ: ETRM): This $2 Weight Loss Stock Could Double Within 6 Months

We are losing the battle of the bulge. Though health care practitioners have been trying to raise awareness about the perils of obesity for a decade, the numbers keep getting worse.

According to a survey conducted by Gallup-Healthways, 27.2% of all Americans are classified as obese, up a full percentage point from 2012. For people aged 45-64, a stunning 32.5% of the population is considered obese. All of those figures go hand-in-hand with rising rates of diabetes and hypertension.

Although investors had been pinning their hopes on obesity drugs offered by Vivus (NASDAQ: VVUS), Orexigen Therapeutics (NASDAQ: OREX) and Arena Pharmaceuticals (NASDAQ: ARNA), the fact that all three of those stocks still trade below $10, despite many years of hype, shows that pill-based approaches have been underwhelming.  (more)

Please share this article